<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141475</url>
  </required_header>
  <id_info>
    <org_study_id>19-PP-07</org_study_id>
    <nct_id>NCT04141475</nct_id>
  </id_info>
  <brief_title>Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy</brief_title>
  <acronym>CARDIALA</acronym>
  <official_title>Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The heart has the ability to respond to different patho-physiological conditions by adapting&#xD;
      its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a&#xD;
      substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the&#xD;
      transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated&#xD;
      that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food&#xD;
      supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of&#xD;
      PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of LVEF between before and after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>percentage of blood ejection before and after 12 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Alpha-Lipoic Acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Physiomance acide lipoïque gold</intervention_name>
    <description>1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks</description>
    <arm_group_label>Alpha-Lipoic Acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo - Physiomance acide lipoïque gold</intervention_name>
    <description>1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult age ≥ 18 years&#xD;
&#xD;
          -  patient with diagnosed type 2 diabetes (history of pathological hyperglycemia&#xD;
             according to WHO and HbA1c standards &gt;7% or ongoing treatment with oral antidiabetic&#xD;
             agents).&#xD;
&#xD;
          -  Patients with stable cardiomyopathy (no hospitalization in cardiology in the month&#xD;
             before inclusion) with a left ventricular ejection fraction (LVEF) &lt;50%.&#xD;
&#xD;
          -  patient who has signed an informed consent form&#xD;
&#xD;
          -  For women of childbearing age: effective contraception followed for at least 3 months&#xD;
             before the start of the study and agreeing to keep it for the duration of the study.&#xD;
&#xD;
          -  affiliation to a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        subjects:&#xD;
&#xD;
          -  With a coronary event in the year before inclusion.&#xD;
&#xD;
          -  With symptoms of cardiac ischemia at inclusion.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Severe renal insufficiency&#xD;
&#xD;
          -  Using antioxidant molecules in the 6 months prior to inclusion.&#xD;
&#xD;
          -  Using drugs that can activate PPARs (Fibrates, Telmisartan, Enalaprilat).&#xD;
&#xD;
          -  Using anti-inflammatory drugs.&#xD;
&#xD;
          -  Suffering from acute infectious diseases and inflammatory diseases.&#xD;
&#xD;
          -  Hypersensitivity or a history of hypersensitivity reaction to gadoteric acid,&#xD;
             meglumine or any drug containing gadolinium.&#xD;
&#xD;
        Non-inclusion criteria related to MRI:&#xD;
&#xD;
          -  with an implanted vascular stent less than 6 weeks before the examination;&#xD;
&#xD;
          -  carrier of an implanted biomedical device deemed &quot;not safe&quot; or &quot;unsafe&quot; in the list:&#xD;
             http://www.mrisafety.com/TheList_search.asp;&#xD;
&#xD;
          -  Beneficiary of an acquisition procedure that does not respect the conditions required&#xD;
             by &quot;conditional&quot; use in a subject carrying an implanted biomedical material considered&#xD;
             &quot;conditional&quot; in the list: http://www.mrisafety.com/TheList_search.asp;&#xD;
&#xD;
          -  carrier of a ferromagnetic intraocular or intracranial foreign body close to the nerve&#xD;
             structures;&#xD;
&#xD;
          -  carrying biomedical equipment such as a cardiac, neural or sensory pacemaker (cochlear&#xD;
             implant) or a ventricular bypass valve without medical and paramedical supervision&#xD;
             trained to perform MRI in these subjects;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emile FERRARI, PUPH</last_name>
    <phone>33 4 92 03 77 35</phone>
    <email>ferrari.e@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile FERRARI, PUPH</last_name>
      <phone>33- 04 92 03 77 35</phone>
      <email>ferrari.e@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>emile FERRARI, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>charlotte DAVID, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

